Lung Cancer | Specialty

Phase II Study Shows Promising Efficacy for Nivolumab in Advanced NSCLC

October 31st 2014

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC

October 31st 2014

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Dr. Govindan on the Potential for Alectinib

October 31st 2014

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

Post-Operative Radiation Therapy Improves Overall Survival in NSCLC Patients

October 31st 2014

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

October 31st 2014

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Second-Line Treatment in NSCLC

October 30th 2014

Discussing Maintenance Therapy in NSCLC

October 30th 2014

Strategies for Delivering Maintenance Therapy in NSCLC

October 30th 2014

Maintenance Therapy in NSCLC

October 30th 2014

First-, Second-, and Third-Line Treatment for NSCLC

October 30th 2014

Adjuvant Versus Neoadjuvant Chemotherapy for NSCLC

October 30th 2014

Histology and NSCLC Treatment

October 30th 2014

Utilizing Treatment Regimens in NSCLC

October 30th 2014

Current Treatment Landscape for NSCLC

October 30th 2014

Molecular Profiling Reveals Potential Targets in SCLC, Lung NETs

October 30th 2014

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

PCP Knowledge Gap Could Affect Lung Cancer Screening Implementation

October 30th 2014

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6

October 30th 2014

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Reducing Lung Biopsies May Cut Costs, Improve Patient Outcomes

October 30th 2014

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

Dr. Gandara Discusses the Future of Clinical Trial Designs

October 30th 2014

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

FDA Grants Breakthrough Therapy Designation to Pembrolizumab for NSCLC

October 27th 2014

The FDA has granted a breakthrough therapy designation to pembrolizumab (Keytruda), an anti-PD-1 therapy, for the treatment of patients with non-small cell lung cancer (NSCLC) who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.